tirzepatide surpass cvot Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study What did the published SURPASS

Common adverse effects include: Gastrointestinal symptoms nausea, vomiting, diarrhoea, constipation, and abdominal pain (affecting up to 40% of users) Reduced appetite and weight loss Injection site reactions redness, itching, or discomfort Hypoglycaemia particularly when used alongside insulin or sulfonylureas More serious but rare adverse effects include pancreatitis (inflammation of the pancreas) and gallbladder disease

This amount is often enough to support fullness while helping preserve lean muscle massparticularly important during weight loss or healthy aging

,

Incorrect dosing and unsafe escalation Lack of support in managing side effects such as nausea, dizziness, and digestive issues Exposure to unsafe or counterfeit products While the upfront cost looks cheaper, the long-term consequences can be both unsafe and ineffective

Looking for a headline-worthy haul

The protein expression of LC3II/LC3I and P62 altered in a similar manner (Fig